How These Biotech Stocks are Faring? -- Agenus, Kite Pharma, Ocular Therapeutix, and Radius Health

NEW YORK, December 15, 2016 /PRNewswire/ --

The iShares Nasdaq Biotechnology ETF (IBB) is down more than 5% over the past month, bringing its year-to-date loss to just over 20%. According to an ETF Trends report, this puts the IBB in bear market territory for the year, and some believe that there could be more declines on the way. Pre-market, Stock-Callers.com shifts focus on four Biotech equities to see how current market conditions have affected their most recent performances: Agenus Inc. (NASDAQ: AGEN), Kite Pharma Inc. (NASDAQ: KITE), Ocular Therapeutix Inc. (NASDAQ: OCUL), and Radius Health Inc. (NASDAQ: RDUS). Register now and get full and free access to our downloadable research reports on these stocks at:

http://stock-callers.com/registration

Agenus 

Massachusetts headquartered Agenus Inc.'s stock finished Wednesday's session 2.76% lower at $4.22 with a total trading volume of 913,484 shares. The Company's shares are trading 13.27% below their 200-day moving average. Shares of the Company, which focuses on the discovery and development of treatments that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 40.08.

On November 30^th, 2016, Agenus announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-OX40 agonist antibody INCAGN1949. The trial is being conducted by, and in collaboration with, Incyte Corp. The open-label, dose-escalation portion of the trial will evaluate the safety and tolerability of INCAGN1949 in patients with advanced or metastatic solid tumors and determine its pharmacologically active and/or maximum tolerated dose. Access our complete research report on AGEN for free at:

http://stock-callers.com/registration/?symbol=AGEN

Kite Pharma 

On Wednesday, shares in California headquartered Kite Pharma Inc. recorded a trading volume of 731,644 shares, and ended the session 2.19% higher at $47.63. The stock is trading 3.10% below its 50-day moving average. Shares of the Company, which focuses on the development and commercialization of novel cancer immunotherapy products, have an RSI of 46.26.

On November 21^st, 2016, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, issuing a target price of $78 per share.

On December 13^th, 2016, Kite Pharma and Vitruvian Networks, Inc., an analytics platform company co-founded by GE Ventures and the Mayo Clinic, announced a strategic partnership to create a software solution to support commercial availability of T-cell therapies. Together, the parties will design and develop a platform for patients, physicians and treatment centers that enables commercial-scale ordering, logistics, monitoring, and delivery of autologous cell therapies if they are FDA-approved, including axicabtagene ciloleucel, Kite's lead investigational engineered T-cell therapy for aggressive non-Hodgkin lymphoma. The complimentary research report on KITE can be downloaded at:

http://stock-callers.com/registration/?symbol=KITE

Ocular Therapeutix 

Shares in Massachusetts headquartered Ocular Therapeutix Inc. closed the day 4.67% lower at $7.97. The stock recorded a trading volume of 652,849 shares. The Company's shares have gained 6.41% in the last month and 20.57% in the previous three months. Additionally, shares of Ocular Therapeutix, which focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the US, have an RSI of 42.52.

On November 15^th, 2016, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $30 a share to $32 a share.

As per a SEC filing dated November 30^th, 2016, Ocular Therapeutix entered into a Controlled Equity Offering SM Sales Agreement on November 29^th, 2016, with Cantor Fitzgerald & Co., as agent, pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share, having an aggregate offering price of up to $40,000,000 from time to time through Cantor Fitzgerald.  Register for free on Stock-Callers.com and get access to the latest PDF format report on OCUL at:

http://stock-callers.com/registration/?symbol=OCUL

Radius Health 

At the close, shares in Waltham, Massachusetts headquartered Radius Health Inc. finished 0.51% lower at $41.28. The stock recorded a trading volume of 1.37 million shares, which was above its three months average volume of 985,720 shares. The Company's shares are trading below their 200-day moving average by 5.24%. Furthermore, shares of Radius Health, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have an RSI of 33.84.

On December 08^th, 2016, Radius Health announced data from two ongoing Phase 1 studies of RAD1901, an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. The company noted that as of the cut-off date of October 07^th, 2016, 20 patients have been treated in the RAD1901 Phase IB safety expansion cohort at the 400 mg dose. Of the enrolled patients, 19 out of 20 had measurable disease at baseline and there were two confirmed partial responses by RECIST criteria. Download your free research report on RDUS at:

http://stock-callers.com/registration/?symbol=RDUS

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number:  +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA